(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-4-oxo-butanoyl]amino]-4-methyl-pentanoyl]amino]-3-methyl-butanoyl]amino]-6-guanidino-hexanoyl]amino]-3-methyl-pentanoyl]amino]acetyl]amino]-4-methyl-pentanoyl]amino]-4-methyl-pentanoyl]amino]-5-guanidino-pentanoic acid

ID: ALA5290775

Chembl Id: CHEMBL5290775

Max Phase: Preclinical

Molecular Formula: C59H100N18O12

Molecular Weight: 1253.56

Associated Items:

Names and Identifiers

Canonical SMILES:  CC[C@H](C)[C@H](NC(=O)[C@H](CCCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(C)C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O

Standard InChI:  InChI=1S/C59H100N18O12/c1-11-34(10)48(55(86)69-29-46(79)70-41(23-30(2)3)51(82)74-42(24-31(4)5)52(83)72-40(57(88)89)20-16-22-67-59(64)65)77-50(81)39(19-14-15-21-66-58(62)63)71-56(87)47(33(8)9)76-54(85)43(25-32(6)7)75-53(84)44(27-45(61)78)73-49(80)37(60)26-35-28-68-38-18-13-12-17-36(35)38/h12-13,17-18,28,30-34,37,39-44,47-48,68H,11,14-16,19-27,29,60H2,1-10H3,(H2,61,78)(H,69,86)(H,70,79)(H,71,87)(H,72,83)(H,73,80)(H,74,82)(H,75,84)(H,76,85)(H,77,81)(H,88,89)(H4,62,63,66)(H4,64,65,67)/t34-,37-,39-,40-,41-,42-,43-,44-,47-,48-/m0/s1

Standard InChI Key:  BJACKHBSJJXIHC-WPYHUPBPSA-N

Alternative Forms

  1. Parent:

    ALA5290775

    ---

Associated Targets(Human)

PCSK9 Tclin Subtilisin/kexin type 9 (362 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 1253.56Molecular Weight (Monoisotopic): 1252.7768AlogP: #Rotatable Bonds:
Polar Surface Area: Molecular Species: HBA: HBD:
#RO5 Violations: HBA (Lipinski): HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: CX LogD:
Aromatic Rings: Heavy Atoms: QED Weighted: Np Likeness Score:

References

1. Ahamad S, Bhat SA..  (2022)  Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment.,  65  (23.0): [PMID:36446632] [10.1021/acs.jmedchem.2c01290]

Source